Houston space health nonprofit launches first experiments onboard Blue Origin mission

all aboard

Houston-based health tech organization had experiments on Blue Origin's last mission. Photo courtesy of Blue Origin

Houston's Translational Research Institute for Space Health, or TRISH, conducted cutting-edge research onboard Blue Origin's New Shepard rocket that launched Friday, November 22.

The NS-28 mission sent private astronauts on an 11-minute suborbital journey past the recognized boundary of space known as the Kármán line, according to Blue Origin's website. While on board, astronauts wore a medical-grade BioButton device, known as a BioIntelliSense, that monitored vital signs and biometric readings.

The findings will add to TRISH's Enhancing eXploration Platforms and ANalog Definition, or EXPAND, program and were the first data sets captured from a suborbital flight.

“This initiative enables TRISH to further our research in space medicine by collecting valuable human health data,” Jimmy Wu, TRISH deputy director and chief engineer and assistant professor at Baylor, said in a statement. “New data from suborbital flights builds our understanding of how the human body responds to spaceflight. This holistic view is key in keeping humans healthy and safe in space.”

The experiments were also TRISH's first on a Blue Origin mission.

TRISH, which is part of BCM’s Center for Space Medicine with partners Caltech and MIT, has launched experiments on numerous space missions to date, with each contributing to its EXPAND platform, which compiles research on human health while in space.

In January, TRISH launched six experiments onboard Houston-based Axiom Space's third private astronaut mission to the International Space Station, known as Ax-3. Prior to that, it also sent experiments on board the Ax-2 in May 2023. The research considered topics ranging from changes in astronauts memory before and after space travel to sleep and motor skills.

TRISH also launched experiments onboard SpaceX's Polaris Dawn mission this fall and on the Inspiration4 all-civilian mission to orbit in 2021.

TRISH published its findings from the Inspiration4 mission in the journal Nature this summer. The study showed that "short-duration missions do not pose a significant health risk" to humans onboard. Read more about the team's findings here.

From Your Site Articles
NASA astronauts Bob Behnken and Doug Hurley are coming home. Photo courtesy of NASA

Here's how to watch the historic NASA/SpaceX splashdown in Houston

return flight

On May 30, the world watched a historic — and uplifting — moment in space travel, as NASA astronauts Robert Behnken and Douglas Hurley blasted off from Earth in a commercial craft created by Elon Musk's SpaceX. The NASA/SpaceX Dragon Endeavour flight was the first launch with astronauts of the SpaceX Crew Dragon spacecraft and Falcon 9 rocket to the International Space Station as part of the agency's Commercial Crew Program.

The SpaceX Demo-2 launch was a success: the duo orbited Earth and eventually boarded the International Space Station; Behnken and Hurley have been stationed there since.''

Now, space fans can watch the return of the NASA/SpaceX Demo-2 test flight, which is scheduled for 1:42 pm CST on Sunday, August 2. The splashdown represents the first return of a commercially built and operated American spacecraft carrying astronauts from the space station, according to NASA. The historic return signifies the close of a mission designed to test SpaceX's human spaceflight system, including launch, docking, splashdown, and recovery operations.

The ever-popular Space Center Houston (the official visitor center of NASA's Johnson Space Center) will stream the live splashdown in a socially distanced event. Visitors can engage in interactive, pop-up science labs to learn about the splashdown process, the specially crafted spacesuits, and more.

To make it a full day of exploration, guests can walk underneath a flown SpaceX Falcon 9 rocket, which is the only Falcon 9 on public display outside of SpaceX's headquarters, and is the same type of rocket used in the Demo-2 mission.

Guests can also take a tour of the Independence Plaza exhibit and walk inside a shuttle replica mounted on top of the historic shuttle carrier aircraft NASA 905. Myriad other experiences await; safety protocols will be in place.

Meanwhile, NASA will broadcast the splashdown coverage on NASA TV and the agency's website beginning early morning on August. 1, with coverage lasting through splashdown on August 2.

------

This article originally ran on CultureMap.

KBR signed a Space Act Agreement with NASA's Johnson Space Center to provide private astronaut training in NASA facilities. Photo via NASA.gov

Houston tech company gets green light from NASA to train commercial astronauts

space tech

For 60 years, Houston-based KBR has supported NASA's astronauts. Now, though a recently signed Space Act Agreement, KBR will also be providing its human spaceflight operation services to commercial companies.

"KBR has pioneered space travel for more than half a century. We will leverage our domain expertise to assist private astronauts with their human spaceflight activities," says Stuart Bradie, KBR President and CEO, in a news release.

The arrangement will include KBR training private astronauts on NASA property — it's the only agreement of its kind. KBR will train for space tasks like operating onboard of the International Space Station, routine operational tasks, health and performance checks, responding to emergencies, and more.

"This historic agreement is a testament to KBR's long standing partnership with NASA. We will continue to work together to propel NASA's mission to fuel a low-Earth orbit economy and advance the future of commercial space," Bradie continues in the release.

Earlier this week, Axiom Space, a Houston-based space tech startup, announced it was selected to design a commercial space flight habitat to be attached to the ISS. KBR is among Axiom's professional partners on the project.

Image---Axiom-modules-connected-to-ISSKBR is one of Axiom Space's partners on its new NASA-sanctioned ISS project. Photo via AxiomSpace.com

The Axiom project includes plans to replace the ISS with a commercially operated space station. The targeted launch date for the commercial destination module is set for late 2024.

Both the Axiom and KBR agreements with NASA are in line with a shift toward commercialization within the space industry. Last June, NASA released its plan to introduce marketing and commercial opportunities to the ISS — with financial expense being a main factory.

"The agency's ultimate goal in low-Earth orbit is to partner with industry to achieve a strong ecosystem in which NASA is one of many customers purchasing services and capabilities at lower cost," reads the release online.

In an interview with InnovationMap last July, NASA Technology Transfer Strategist Steven Gonzalez explains that opening up the space industry to commercial opportunities allows for NASA to focus on research. The government agency doesn't need to worry about a return on investment, like commercial entities have to.

"With the commercial market now, people keep talking about it being a competition, but in reality we need one another," Gonzalez says. "We have 60 years of history that they can stand on and they are doing things differently that we're learning from."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

View All Listings